Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Hae Lim, Yu Su Jong, Lee Sung Hak, Lee Min Woo, Lee Han Ah, Cho Yuri, Yoo Jeong-Ju, Kim Ha Il, Lee Jae Geun, Lee Hye Won, An Jihyun, Yim Sun Young, Sung Pil Soo, Choi Jonggi, Yoon Jae Hyun, Cho Eun Ju, Jung Jinhong, Hyun Dongho, Joo Ijin, Lee Yu Rim, Choi YoungRok, Kim Bo Hyun, Kim Sung Hyun, Kim Soon Sun, Kim Jeong-Han, Kim Haeryoung, Park Pyoung-Jae, Shin Hyun Phil, Yoon Ki Tae, Yoon Sang Min, Lee Minjong, Cho Jai Young, Choi Jin-Young, Kim Do Young, Lee June Sung, Kim Mi-Sook, Kim Kyung Sik, 26th Scientific Committee of the Korean Liver Cancer Association
Аннотация
The role of liver biopsy in hepatocellular carcinoma (HCC) is being re-evaluated in the era of precision oncology and biomarker-driven systemic therapy. Although histopathological examination remains the diagnostic gold standard, HCC is unique among solid tumors in that accurate non-invasive imaging criteria allow diagnosis without routine biopsy in selected clinical settings. However, increasing biological heterogeneity, expanding therapeutic options, and the growing need for molecular stratification have renewed interest in tissue-based evaluation. Recent international guidelines have gradually broadened the indications for liver biopsy, particularly in selected diagnostic scenarios, prior to systemic therapy, and for molecular profiling. Beyond diagnostic confirmation, liver biopsy provides important information for histological subtyping, prognostic stratification, and biomarker discovery. Advances in immunohistochemistry, next-generation sequencing, and artificial intelligence-assisted pathology have further enhanced the clinical value of tumor tissue. In parallel, contemporary cohort studies indicate that liver biopsy is associated with low complication rates when modern techniques and standardized peri-procedural management are applied. Despite these advances, the integration of liver biopsy into routine clinical practice remains limited. To contextualize this gap, the Korean Liver Cancer Association conducted a nationwide survey of HCC specialists. The survey showed that liver biopsy is infrequently performed in current practice due to perceived procedural risks and limited immediate impact on therapeutic decision-making. Taken together, accumulating evidence supports a reappraisal of the clinical role of liver biopsy in HCC. Optimizing procedural safety, standardizing indications, and integrating tissue-based molecular insights into therapeutic decision-making may help bridge the gap between emerging evidence and real-world practice.